Medivir AB engages in the development of pharmaceuticals against infectious diseases. It operates through the following segments: Pharmaceuticals and Parallel Imports. The Pharmaceuticals segment develops, produces and markets new products under the Xerclear brand name and BioPhausia's portfolio. The Parallel Imports segment brings in pharmaceuticals from European Union countries to Sweden, and operates through BioPhausia's subsidiary, Cross Pharma. The company was founded in 1988 and is headquartered in Stockholm, Sweden.